Genotype vs Clinically Guided Dosing of Warfarin to Prevent Adverse Events: In reply

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	1279-1280
Number of pages	2
Journal	JAMA - Journal of the American Medical Association
Volume	319
Issue number	12
DOIs	https://doi.org/10.1001/jama.2018.0195
State	Published - Mar 27 2018

Access to Document

@article{14534b5e7aa545dcaa171f833ccc5827,

title = "Genotype vs Clinically Guided Dosing of Warfarin to Prevent Adverse Events: In reply",

author = "Gage, {Brian F.} and Bass, {Anne R.} and Eby, {Charles S.}",

year = "2018",

month = mar,

day = "27",

doi = "10.1001/jama.2018.0195",

language = "English",

volume = "319",

pages = "1279--1280",

journal = "Journal of the American Medical Association",

issn = "0098-7484",

number = "12",

}

TY - JOUR

T1 - Genotype vs Clinically Guided Dosing of Warfarin to Prevent Adverse Events

T2 - In reply

AU - Gage, Brian F.

AU - Bass, Anne R.

AU - Eby, Charles S.

PY - 2018/3/27

Y1 - 2018/3/27

UR - http://www.scopus.com/inward/record.url?scp=85044463758&partnerID=8YFLogxK

U2 - 10.1001/jama.2018.0195

DO - 10.1001/jama.2018.0195

M3 - Letter

C2 - 29584836

AN - SCOPUS:85044463758

VL - 319

SP - 1279

EP - 1280

JO - Journal of the American Medical Association

JF - Journal of the American Medical Association

SN - 0098-7484

IS - 12

ER -